Cutting-edge research suggests that engineered mesenchymal stem cells (MSCs) could disrupt this ... improving the targeted delivery of therapies. When iMSCs are derived from iPSCs, they can ...

BrainStorm gets US FDA nod to begin phase 3b trial of NurOwn to treat amyotrophic lateral sclerosis: New York Wednesday, May 21, 2025, 18:00 Hrs [IST] BrainStorm Cell Therapeutics ...

Stem cells sound vaguely futuristic but they are increasingly being used in a wide range of medical applications. Their ...

BrainStorm Cell Therapeutics Inc. , a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the ...

Forthcoming press releases will feature additional notable oral abstracts. More information on all MD Anderson ASCO Annual ...

Investor call and webcast scheduled for today at 8:30 a.m. ET NEW YORK, May 19, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading ...

The FDA has granted Mesoblast’s stem cell therapy, Ryoncil (remestemcel-L), seven years of orphan drug exclusivity for the ...

Research teams funded by the National Institutes of Health (NIH) have created a versatile set of gene delivery systems that can reach different neural cell types in the human brain and spinal cord ...

Cells are the smallest units of life. But even within the same tissue or organ, they are not all identical. New variations arise continuously during cell proliferation. While genetic mutations alter ...